SCHEMBL5365559

SCHEMBL5365559

COc1cc(C=C2C(=O)Nc3ccc(S(=O)(=O)Nc4ccc(C(F)(F)F)cc4)cc32)cc(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MOGAT2 Q3SYC2 5/20 0.56
MGAT2 Q10469 3/20 0.53
MEN1 O00255 1/20 0.50
ALOX15 P16050 1/20 0.50
MAPK1 P28482 1/20 0.50
KMT2A Q03164 1/20 0.50
MGAT1 P26572 1/20 0.47
BRD4 O60885 1/20 0.46
SYK P43405 5/20 0.46
PKM P14618 1/20 0.46
NTRK1 P04629 2/20 0.45
NTRK3 Q16288 2/20 0.45
NTRK2 Q16620 2/20 0.45
FCER2 P06734 1/20 0.45
LRRK2 Q5S007 1/20 0.44
RORA P35398 1/20 0.44
RORC P51449 1/20 0.44
NR1H2 P55055 1/20 0.44
RET P07949 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369913 0.93 MOGAT2 (0.56) MOGAT2MGAT2MEN1ALOX15MAPK1
SCHEMBL5363156 0.90 MOGAT2 (0.55) MOGAT2MGAT2MEN1ALOX15MAPK1
SCHEMBL5369240 0.89 LRRK2 (0.57) MOGAT2MGAT2MEN1ALOX15MAPK1
SCHEMBL5364814 0.89 GSK3B (0.57) MOGAT2MGAT2MEN1ALOX15MAPK1
SCHEMBL5358368 0.88 MOGAT2 (0.61) MOGAT2MGAT2MEN1ALOX15MAPK1
SCHEMBL7135580 0.88 MOGAT2 (0.50) MOGAT2MGAT2MEN1ALOX15MAPK1
SCHEMBL7140002 0.88 MOGAT2 (0.56) MOGAT2MGAT2MEN1ALOX15MAPK1
SCHEMBL5367172 0.88 ERBB2 (0.54) MOGAT2MGAT2MEN1ALOX15MAPK1
SCHEMBL5364979 0.87 MEN1 (0.61) MOGAT2MGAT2MEN1ALOX15MAPK1
SCHEMBL5363178 0.87 MOGAT2 (0.52) MOGAT2MGAT2MEN1ALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MOGAT2 1159/4885MGAT2 4714/4885MEN1 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.